ChiCTR2400088699 版本V1.0 版本创建时间2024/08/26 08:45:43 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400088699 

最近更新日期:

Date of Last Refreshed on:

2024-08-26 08:44:56 

注册时间:

Date of Registration:

2024-08-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

R/I指数指导下的ARDS肺可复张性评估与炎症表型的相关性研究

Public title:

Correlation between R/I index guided assessment of ARDS lung reexpansibility and inflammatory phenotype

注册题目简写:

English Acronym:

研究课题的正式科学名称:

R/I指数指导下的ARDS肺可复张性评估与炎症表型的相关性研究

Scientific title:

Correlation between R/I index guided assessment of ARDS lung reexpansibility and inflammatory phenotype

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

何梦菲 

研究负责人:

何梦菲 

Applicant:

He Mengfei 

Study leader:

He mengfei 

申请注册联系人电话:

Applicant telephone:

+86 18792653389

研究负责人电话:

Study leader's telephone:

+86 18792653389

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1584274580@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1584274580@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

西安交通大学第二附属医院重症医学科

研究负责人通讯地址:

皇城西路30号交大二院南院

Applicant address:

Department of Critical Care Medicine, the Second Affiliated Hospital of Xi 'an Jiaotong University

Study leader's address:

Second Affiliated Hospital of Xian Jiaotong University Xian 710004 Shaanxi Province China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西安交通大学第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Xi 'an Jiaotong University

研究负责人所在单位:

西安交通大学第二附属医院

Affiliation of the Leader:

Xi'an Jiaotong University Second Affiliated Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024伦审030

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安交通大学第二附属医院 医学伦理委员会

Name of the ethic committee:

The medical ethics committee of the Second Affiliated Hospital of Xi'an Jiaotong University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-03-05 00:00:00

伦理委员会联系人:

李涵

Contact Name of the ethic committee:

Li Han

伦理委员会联系地址:

皇城西路30号交大二院南院

Contact Address of the ethic committee:

Second Affiliated Hospital of Xian Jiaotong University Xian 710004 Shaanxi Province China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 15339222105

伦理委员会联系人邮箱:

Contact email of the ethic committee:

lunli326@163.com

研究实施负责(组长)单位:

西安交通大学第二附属医院

Primary sponsor:

Xi'an Jiaotong University Second Affiliated Hospital

研究实施负责(组长)单位地址:

皇城西路30号交大二院南院

Primary sponsor's address:

Second Affiliated Hospital of Xian Jiaotong University Xian 710004 Shaanxi Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第二附属医院

具体地址:

皇城西路30号交大二院南院

Institution
hospital:

Xi'an Jiaotong University Second Affiliated Hospital

Address:

Second Affiliated Hospital of Xian Jiaotong University Xian 710004 Shaanxi Province China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

self-raised

Target disease:

acute respiratory distress syndrome

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

评估ARDS患者肺可复张性与炎症表型的相关性。  

Objectives of Study:

To evaluate the correlation between pulmonary reexpansibility and inflammatory phenotype in ARDS patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥ 16岁;
2.诊断为中度或重度ARDS(动脉血氧分压与吸入氧浓度之比,PaO2/ FiO2≤200mmHg)(2023年ARDS新定义);
3.有创机械通气;
4.留置有创动脉导管;

Inclusion criteria

1.Age ≥ 16 years;
2.Diagnosed with moderate or severe ARDS (ratio of arterial partial pressure of oxygen to inhaled oxygen concentration, PaO2/ FiO2≤200mmHg) (new definition of ARDS in 2023);
3.Invasive mechanical ventilation;
4.Indwelling an invasive arterial catheter;

排除标准:

1.气胸;
2.血流动力学不稳定(最近6小时内血管加压药增加>30%或去甲肾上腺素>0.5μg/kg/min);
3.根据《全球慢性阻塞性肺疾病倡议》标准,严重或非常严重的COPD;
4.临床怀疑颅内压升高>18mmHg;

Exclusion criteria:

1.pneumothorax;
2.Hemodynamic instability (increased vasopressors within the last 6 hours) 30% or noradrenaline >
0.5μg/kg/min);
3.Severe or very severe COPD according to the Global COPD Initiative criteria;
4.Clinically suspected elevated intracranial pressure >
18mmHg;

研究实施时间:

Study execute time:

From 2024-09-01 00:00:00 To 2026-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-09-01 00:00:00 To 2026-09-01 00:00:00  

干预措施:

Interventions:

组别:

高可复张组

样本量:

45

Group:

High retensibility group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

低可复张组

样本量:

45

Group:

Low reproducible group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China 

Province:

Shaanxi 

City:

 

单位(医院):

西安交通大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

Xi'an Jiaotong University Second Affiliated Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China 

Province:

Shaanxi 

City:

 

单位(医院):

西安交通大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

Xi'an Jiaotong University First Affiliated Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

炎症指标:内毒素、白细胞介素-6(IL-6)、中性粒细胞弹性蛋白酶(肺泡灌洗液)

指标类型:

主要指标

Outcome:

Inflammatory index:Endotoxin, interleukin-6 (IL-6), Neutrophil elastase (alveolar lavage fluid)

Type:

Primary indicator

测量时间点:

机械通气24小时内

测量方法:

检验科临床检验、elisa实验

Measure time point of outcome:

Mechanical ventilation within 24 hours

Measure method:

clinical examination、elisa experiment

指标中文名:

炎症指标:肿瘤坏死因子-α(TNF-α) 、可溶性肿瘤坏死因子受体-1(sTNFr-1)(血)、晚期糖基化终末产物的可溶性受体(sRAGE)(血)

指标类型:

次要指标

Outcome:

Inflammatory index:TNF-α、sTNFr-1、sRAGE

Type:

Secondary indicator

测量时间点:

机械通气24小时内

测量方法:

检验科临床检验、elisa实验

Measure time point of outcome:

Mechanical ventilation within 24 hours

Measure method:

clinical examination、elisa experiment

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 16 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

与项目负责人联系

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact the project leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

“陕西省重大疾病防控与大健康数据共享平台数据采集系统”已建立,并已完善CRF表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

"Shaanxi Province Major disease prevention and control and big health data sharing platform data collection system" has been established, and has improved the CRF table

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-08-26 08:44:56